Alzheimer Disease Research Center (ADRC)
Resveratrol


Resveratrol: A New Clinical Trial for People with Alzheimer’s Disease

The purpose of the resveratrol clinical trial is to evaluate its safety and effectiveness for people with Alzheimer’s disease.  The US Food and Drug Administration, the FDA, has not approved resveratrol; and we do not know whether its use can change the course the disease. 

In this study, people with AD will be given either resveratrol or placebo for 12 months to see if it can improve or delay the worsening of memory and daily functioning.  Participants can continue their AD treatments prescribed by their doctors, but they cannot be enrolled in another clinical study during this time. 

To be eligible for the study persons must be 50 years of age or older, diagnosed with mild-to-moderate AD, fluent in English or Spanish, be able to abstain from large quantities of resveratrol-containing foods (including red wine and grape juice), and have a study partner to accompany the participant to 10 clinic visits over the 12 months.  There will also be two lumbar punctures and three MRIs that participants will undergo in order to study the effect of resveratrol on the brain.

Click a link below for more Information:

Links for Patients and Family Members